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Malignant transformation entails important changes in the control of cell proliferation through 
the rewiring of selected signaling pathways. Cancer cells become then very dependent on the 
proper function of those pathways, and their inhibition offers therapeutic opportunities. Here we 
identify the stress kinase p38a as a non-oncogenic signaling molecule that enables the 
progression of KrasG12V-driven lung cancer. We demonstrate in vivo that despite acting as a tumor 
suppressor in healthy alveolar progenitor cells, p38α contributes to the proliferation and 
malignization of lung cancer epithelial cells. We show that high expression levels of p38a 
correlate with poor survival in lung adenocarcinoma patients, and that genetic or chemical 
inhibition of p38a halts tumor growth in lung cancer mouse models. Moreover, we reveal a lung 
cancer epithelial cell autonomous function for p38a promoting the expression of TIMP-1, which 
in turn stimulates cell proliferation in an autocrine manner. Altogether, our results suggest that 
epithelial p38a promotes KrasG12V-driven lung cancer progression via maintenance of cellular 





Nearly half of the cases of lung cancer bear mutations in the RAS pathway. Unfortunately, no 
specific drugs are available to successfully target many RAS-driven tumors that are not 
surgically resectable. Despite the sound rationale for targeting oncogene products for cancer 
therapeutics, this often leads to development of resistance. As an alternative, non-oncogenic 
proteins can sometimes facilitate tumor progression, and even though they are neither mutated 
nor over-expressed in the malignant cells, they may represent potential targets for anti-cancer 
therapies. We have found that non-oncogenic signaling through p38α plays a tumor promoting 
function in lung adenocarcinoma epithelial cells by inducing the expression of TIMP-1, a growth 







Despite the many efforts invested during the past decades, the development of selective therapies 
remains one of the biggest challenges in oncology. Nowadays, lung adenocarcinomas in 
advanced stages, like those driven by mutations in EGFR or ALK, are often treated with tyrosine 
kinase inhibitors but, unfortunately, tumors tend to become resistant in less than a year and 
continue to progress (1, 2). The development of targeted therapies for KRAS-induced lung 
tumors has proven especially difficult. Most of the mutated KRAS forms lack suitable pockets to 
which drugs can bind in order to interfere with the oncogenic function, and targeting some of the 
downstream kinases leads to undesirable toxicities (3). An alternative approach consists on 
targeting synthetic lethal partners of the mutated KRAS, so that cancer cells have their viability 
compromised, while the normal cells without the mutated driver gene are not affected. When 
these partners do not have oncogenic activity themselves, the exacerbated dependency of the 
cancer cell for their function has been termed “non-oncogene addiction” (4). This is the case for 
the transcription factor GATA2 whose deletion induces the regression of established KRAS 
mutant lung tumors in mice (5). Therefore, charting a comprehensive map of non-oncogene 
addictions in KRAS-driven cancer may help to develop new therapies. 
The protein kinase p38a, also known as mitogen-activated protein kinase (MAPK) 14, is 
normally stimulated by environmental stresses and other cues, orchestrating cell responses like 
proliferation, differentiation, or apoptosis depending on the stimulus and the cell type (6, 7). In 
the tumor context, p38a has been shown to interfere with malignant cell transformation in 
different tissues (8-10). In particular, p38a has been reported to suppress lung tumor formation, a 
function that is probably related to its ability to induce the differentiation of progenitor cells (9). 
Curiously, no functionally significant genomic alterations for p38a have been described in 
tumors, and there is evidence that p38a might be constitutively phosphorylated in several cancer 
types (11-13). In fact, immunohistochemistry and phospho-proteomic analysis have reported 
phosphorylated p38α in the tumors from non-small-cell lung carcinoma (NSCLC) patients (14-
16). Both the scarcity of inactivating mutations and the presence of phosphorylated p38a in 
tumors suggest the possibility that cancer cells may use this non-oncogenic signaling pathway to 
facilitate tumor progression. Consistent with this notion, epithelial cancer cells in the intestine 
have been shown to exploit p38a for colon tumor maintenance in vivo (10). However, whether 
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p38a in epithelial cancer cells of other tissues contributes to tumor progression remains to be 
explored. Indeed, it is important to contextualize the outcomes of p38α inhibition in the different 
cell types of a tissue as well as the global effect of its ubiquitous downregulation given that the 
complex regulation of survival/death signals by p38 MAPKs can result in opposite molecular 
functions during tumor development, as it has been reported in UV-induced skin papillomas (17, 
18) or in pancreatic ductal adenocarcinomas (19, 20). There is evidence that p38a in stromal 
cells can support lung tumorigenesis (21), and facilitate metastatic lung cell extravasation (22), 
but the contribution of p38a signaling in lung cancer epithelial cells to tumor maintenance and 
progression has not been investigated yet.  
In this study, we have used mouse models of KrasG12V-driven lung cancer and spheroid 
cultures of lung cancer cells to show a tumor-promoting role of epithelial p38a in established 
lung tumors.  
 
RESULTS 
p38a expression correlates with malignancy and poor prognosis in lung adenocarcinoma 
patients. To investigate the role of p38a in lung cancer, we first analyzed the expression levels 
of the MAPK14 gene (encoding p38a) in a cohort of lung adenocarcinoma patients, formed by 
107 tumor samples in stages I to IV. The levels of MAPK14 mRNA were significantly increased 
in the tumors in comparison to the paired normal parenchyma (Fig. 1A). Next, in two other 
different cohorts of 293 and 138 samples of tumors in stages I to III with patient follow-up data, 
we observed that, irrespective of the tumor stage, the highest level of MAPK14 expression 
correlated with a higher mortality rate (Fig. 1B), as well as with a shorter time to relapse in lung 
adenocarcinoma patients both in general (Fig. 1C) and in Kras-driven adenocarcinoma cohorts 
(See SI Appendix, fig. S1A and B). To confirm the results obtained by analyzing public mRNA 
datasets, we used antibodies against phosphorylated p38 or total p38a to stain a human tissue 
microarray, which contained samples of lung adenocarcinomas and paired adjacent normal lung 
tissue, as well as normal lung tissue from patients without tumors. In line with the mRNA 
analysis, we observed that lung tumors contained a higher number of both phosphorylated p38 
and p38a-positive cells than the normal lung parenchyma (Fig. 1D and E).   
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In parallel, we used mice expressing Kras+/FSFG12V, which develop lung adenocarcinomas 
upon intratracheal administration of adenoviruses expressing FlpO recombinase (23). 
Immunohistochemistry analysis confirmed a significantly increased phospho-p38 staining in 
KrasG12V-driven lung tumors compared to the healthy parenchyma (Fig. 1F), supporting our 
observations in the lung adenocarcinoma-patient cohorts. Altogether, these results hint the 
implication of p38a in lung cancer, and suggest that its expression levels could be used as an 
independent prognostic factor for lung adenocarcinoma. 
 
Downregulation of p38a in alveolar epithelial progenitor cells enhances KrasG12V lung 
tumorigenesis but compromises tumor progression. The correlation between MAPK14 (p38a) 
expression and lung tumor malignancy was unexpected, given that p38a downregulation has 
been reported to sensitize lung tissue to KrasG12V-induced oncogenic transformation (9). When 
mice have p38a ubiquitously downregulated, they exhibit uncontrolled proliferation of the 
alveolar epithelial type II (AE2) progenitor cells (8, 9), which can function as lung 
adenocarcinoma initiating cells (24, 25). However, since tumor-associated stromal cells can also 
regulate tumorigenesis, we investigated the role of p38a particularly in the alveolar progenitor 
cells during lung tumor development. To address this, we induced KrasG12V expression in lungs 
of mice carrying Mapk14lox/lox alleles and the surfactant protein C (SPC)-Cre-ER transgene, in 
which Mapk14 can be specifically deleted in AE2 cells (Fig. 2A, and see SI Appendix, fig. S1C). 
When these mice were treated with tamoxifen, we observed a 25% downregulation of the floxed 
exon 2 of Mapk14 in AE2 progenitor cells both by qRT-PCR (See SI Appendix, fig. S1D) and by 
using a double-fluorescent Cre reporter (See SI Appendix, fig. S1E). Consistently, 20 weeks 
after KrasG12V expression, mice with AE2 cell-specific downregulation of p38a (p38a-ΔSPC) 
showed numerous lung tumors constituted by SPC+ cells growing along the preexisting alveolar 
framework. The p38a-ΔSPC tumors showed a significantly increased percentage of proliferative 
cells, as marked by Ki67 staining, compared to their wild-type (WT) counterparts (Fig. 2B). We 
also observed an increased lung weight in p38a-ΔSPC; KrasG12V mice (See SI Appendix, fig. S1F), 
as well as enhanced recruitment of immune cells in their lungs (Fig. 2C), which correlated with 
increased STAT3 phosphorylation (See SI Appendix, fig. S1G), a well-known mediator of 
tumor-promoting inflammation. Accordingly, p38a-ΔSPC mice showed increased lung tumor 
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burden (Fig. 2D). Taken together, these results support a tumor suppressor role of p38a in AE2 
progenitor cells of the lung epithelia. 
Surprisingly, the increased lung tumor burden observed in KrasG12V expressing p38a-ΔSPC 
mice correlated with a higher percentage of early stage hyperplasias versus adenomas, compared 
with the tumors in KrasG12V expressing WT mice, in which there were more adenomas than 
hyperplasias (Fig. 2E). These observations suggest that p38a downregulation facilitates tumor 
initiation, but once the lung epithelial cells are transformed, the absence of p38a delays tumor 
progression to more advanced stages, hinting a possible tumor-promoting role for p38a in lung 
cancer cells. 
 
p38a promotes KrasG12V-driven lung tumor growth. If p38a is required for lung tumor 
progression, the acute loss of p38α in established tumors would be expected to hinder tumor 
growth. To test this hypothesis, we first looked at the effect of the ubiquitous downregulation of 
p38a using p38a-ΔUb mice, which bear Mapk14lox/lox alleles and the tamoxifen-inducible 
Ubiquitin C (UBC)-Cre-ERT2 transgene. The efficiency of p38a downregulation was confirmed 
by immunoblotting and PCR in both whole-lung lysates and individual tumors (Fig. 3A, and see 
SI Appendix, fig. S2A and B). Noteworthy, the levels of both total p38α and phosphorylated-p38 
were higher in lungs expressing oncogenic KrasG12V than in healthy lung tissue (Fig. 3A). 
Therefore, we induced KrasG12V expression, confirmed the presence of lung tumors twenty weeks 
later and then induced p38α downregulation (Fig. 3B). Interestingly, the downregulation of p38a 
resulted in a significantly decreased number and size of macroscopic lung tumors in comparison 
to the tamoxifen-treated WT mice (Mapk14lox/lox without UBC-Cre-ERT2) (Fig. 3C). Indeed, the 
number and size of lung tumors in p38a-ΔUb mice were similar to those in animals analyzed at 
the initial time point, prior to tamoxifen injections, suggesting that p38a downregulation 
produced a cytostatic effect. In contrast, WT animals treated with tamoxifen showed a 
substantial increase in both the number of tumors and the average tumor size in comparison to 
the animals analyzed before p38a downregulation (Fig. 3C). This indicates that tamoxifen by 
itself does not interfere with lung tumor growth. As an additional control, we performed the 
same experiment using mice bearing UBC-Cre-ERT2 and Mapk14+/+ alleles and found no 
significant differences upon tamoxifen treatment between WT mice and the Mapk14+/+;UBC-
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Cre-ERT2 control group neither in lung tumor number nor in size, ruling out any effect related to 
the Cre recombinase activity by itself (See SI Appendix, fig. S2C). Histological analysis of the 
tumors showed a remarkable decrease in the percentage of advanced lesions in p38a-ΔUb mice, 
with adenocarcinomas being decreased 3-fold (Fig. 3D). Collectively, these results further 
support the decreased ratio of advanced versus early lesions observed in p38a-ΔSPC lungs, and 
suggest that KrasG12V-driven lung tumors are addicted to p38a signaling. 
To investigate the cause of the reduced lung tumor load observed upon 
p38a downregulation, we performed immunohistochemistry analysis of lung sections. We found 
that infiltrating lymphocytes (CD3+), which remained mainly at the periphery of the tumors, and 
macrophages (CD68+) were present in similar numbers in WT and p38a-ΔUb animals. Blood 
vessel distribution, as determined by CD31+ staining, was also similar in tumors from both 
groups of mice. Likewise, we detected no differences in the number of apoptotic cells, neither by 
TUNEL nor by cleaved-caspase 3 staining (See SI Appendix, fig. S2D-F). However, the number 
of proliferating cells, as determined by Ki67 immunostaining, was significantly diminished in 
lung tumors from p38a-ΔUb mice (Fig. 3E). Therefore, the acute loss of p38a in developing lung 
tumors does not alter the numbers of infiltrating immune cells or the vasculature density, but it 
impairs cancer cell proliferation and tumor progression to more advanced stages. 
 
Chemical inhibition of p38a reduces lung tumor burden in mice. The dependency of lung 
tumor progression on p38a is a potentially relevant observation from a clinical perspective. As a 
proof of principle, we used the low molecular weight chemical compound PH797804 to inhibit 
the kinase activity of p38a. Mice in which KrasG12V lung tumors had been induced 20 weeks 
before, were administered either PH797804 or vehicle solution via oral gavage for 14 days. We 
found that mice treated with the p38a inhibitor showed a significant decrease in the number and 
size of lung tumors in comparison to the vehicle-treated group (Fig. 4A). Inhibition of p38a 
signaling in the lungs was confirmed by immunoblotting analysis of Hsp27 phosphorylation, a 
downstream target of the pathway (Fig. 4B). Moreover, we observed that the number and size of 
lung tumors in mice treated with PH797804 were similar to those found before the treatment, 
suggesting that p38a inhibition produces a cytostatic effect. In addition, the number of advanced 
lesions, as well as the percentage of Ki67+ cells per tumor were significantly reduced (Fig. 4C 
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and D). These results mirror our observations in p38a-ΔUb mice and show that the role of p38a 
promoting lung tumor progression is mediated through its kinase activity. Moreover, these 
results suggest that p38α inhibition could be potentially useful for NSCLC therapy. 
 
Epithelial p38a is necessary for the proliferation of lung cancer cells in anchorage-
independent conditions. To investigate how p38a contributes to the progression of lung tumors, 
we tried to induce p38a deletion in epithelial cells using mice bearing SPC-Cre-ER and 
Kras+/FSFG12V alleles but, since Cre activity was limited to roughly 25% of the AE2 cells (See SI 
Appendix, fig. S1D and E), the level of p38a knocked-down cells in the tumors was insufficient 
to draw conclusions. Therefore, to study the role of p38a in malignant lung epithelial cells, we 
established ex vivo cultures of cancer cells (named mKLC) isolated from murine KrasG12V lung 
adenocarcinomas (26). We used mice with Mapk14lox/lox alleles so that Mapk14 can be deleted in 
the mKLC cells upon Cre recombinase expression, to generate p38a-deficient cells (p38a-
ΔmKLC). We confirmed that mKLC cells expressed the EpCAM epithelial marker and retained E-
cadherin expression upon p38a downregulation (See SI Appendix, fig. S3A and B). We first 
looked at the proliferation capacity of the mKLC cells in vitro. Strikingly, we observed no 
differences in their cell cycle or their ability to incorporate 5-bromo-2'-deoxyuridine (BrdU) 
when cultured in standard monolayer conditions (See SI Appendix, fig. S3C and D). Similarly, 
Lewis lung carcinoma (LLC1) murine cells with p38a downregulated by shRNAs showed no 
differences with WT cells in BrdU incorporation (See SI Appendix, fig. S3E and F) and had no 
growth advantage when injected subcutaneously into the rare flanks of nude mice (See SI 
Appendix, fig. S3G).   
Interestingly, when mKLC cells were cultured in soft agar to mimic tumor growth, we 
observed that WT and p38a-ΔmKLC cells formed a similar number of colonies after 20 days in 
culture but p38a-ΔmKLC colonies were significantly smaller (Fig. 5A). In a complementary 
experiment, we noticed that inducing the downregulation of p38a in established colonies formed 
by mKLC cells slowed down their growth (See SI Appendix, fig. S3H). These results were 
confirmed using H358 human lung cancer cells, which also formed smaller colonies in soft agar 
in the presence of two different p38α chemical inhibitors (See SI Appendix, fig. S3I). 
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Consistent with the above observations, both WT and p38a-ΔmKLC cells intratracheally 
implanted in immunocompetent mice formed a similar number of lung tumors (Fig. 5B). 
However, tumors formed by p38a-ΔmKLC cells showed a significantly decreased size and less 
proliferative cells (Fig. 5C and D). Likewise, we implanted mKLC cells expressing Cre-ERT2 
intratracheally into C57BL/6 mice and, once lung tumors were formed, p38α downregulation 
was induced in vivo. We found that p38α downregulation significantly diminished the number 
and size of the lung tumors (Fig. 5E), phenocopying the results observed using the UBC-Cre-
ERT2;Kras+/FSFG12V mice. Importantly, these data indicate that the proliferation assays in 2D cell 
cultures and subcutaneous xenografts do not reproduce the in vivo scenario in lung tumors upon 
p38α downregulation. Instead, p38a signaling appears to have an important contribution to the 
proliferation of KrasG12V-driven epithelial lung cancer cells when these cells are challenged by 
culturing in anchorage-independent conditions or by orthotopic implantation in mice. 
To further understand the role of p38α in lung tumor progression, we investigated the 
effect of p38a depletion on the metastatic features of mKLC cells. We found that both WT and 
p38a-deficient cells showed equivalent adhesion and migration capacities, resistance to anoikis, 
and extravasation abilities (See SI Appendix, fig. S4A-D). We next confirmed these results by 
implanting WT and p38a-ΔmKLC cells into the rare flanks of immunodeficient mice. The number 
of lung metastatic foci detected two weeks after primary tumor resection was similar in both 
groups, indicating a similar ability of p38a-ΔmKLC and WT cells to disseminate and colonize the 
lung (See SI Appendix, fig. S4E). However, when we injected LLC1 cells through the tail vein 
of nude mice, we observed two weeks later a smaller lung tumor burden in animals injected with 
p38a-deficient cells (See SI Appendix, fig. S4F). The difference in lung tumor area but not in 
metastatic dissemination ability suggests that p38a does not impact on the metastatic properties 
of the epithelial lung cancer cells, but mainly affects their proliferation rate and hence the tumor 
mass growth rate. 
 
p38a-mediated expression of TIMP-1 induces lung cancer cell proliferation. There is 
evidence that p38a can regulate both the expression of cytokines and the transducing signaling 
pathways engaged by these factors, which can stimulate cancer cell proliferation (11). Therefore, 
we analyzed the possibility that secreted factors controlled by p38a could self-stimulate the 
	 10	
proliferation of lung cancer cells. We used an antibody array to check the expression of 40 
cytokines in lung tumors formed by the orthotopic inoculation of either WT or p38a-ΔmKLC cells, 
and validated the results in individual tumors by qRT-PCR (See SI Appendix, fig. S5A-C). We 
identified TIMP-1 as one of the most significantly downregulated cytokines (Fig. 6A). 
Moreover, p38α downregulation in lung tumors resulted in decreased levels of Timp1 mRNA 
(Fig. 6B). Accordingly, TIMP-1 protein levels in p38α-deficient mouse lungs, either healthy or 
bearing KrasG12V-driven tumors, were decreased in comparison to the equivalent WT lungs (Fig. 
6C). 
TIMP-1 is an inhibitor of matrix metalloproteinases that can also promote lung tumor 
growth through its binding to CD63 (27), and is usually expressed at high levels in lung cancer 
patients with poor prognosis (28, 29). Hence, we investigated whether the reduced Timp1 
expression was responsible for the impaired proliferation of p38a-deficient lung cancer cells. 
First, we analyzed Timp1 mRNA levels in epithelial cancer cells sorted from mouse lung tumors, 
and observed that Timp1 expression was dependent on p38a (See SI Appendix, fig. S5D). We 
also obtained evidence of TIMP-1 implication in epithelial lung cancer cell proliferation by using 
two different TIMP-1 shRNAs, which reduced the size of colonies formed by mKLC cells grown 
in soft agar, an effect that was attenuated in the presence of recombinant TIMP-1 (Fig. 6D and 
E). Moreover, the addition of recombinant TIMP-1 also rescued the decreased colony size 
observed in p38a-deficient mKLC cells grown in soft agar (Fig. 6F). Similar results were 
observed adding recombinant TIMP-1 to human H460 and murine mKLC cells treated with 
p38a chemical inhibitors (Fig. 6G, and see SI Appendix, fig. S5E). Interestingly, analysis of 
public gene expression databases revealed a direct correlation between the expression of Timp1 
and MAPK14 mRNAs in human adenocarcinomas (See SI Appendix, fig. S5F). Therefore, the 
proliferation of lung cancer epithelial cells is regulated by the levels of TIMP-1 which, in turn, 
are controlled by p38α. 
In fact, the p38α regulated transcription factors AP-1 and ATF-2 have binding sites on 
the Timp1 promoter, which also contains two NFkB binding sites (30), and the NFkB pathway 
has been shown to control TIMP-1 levels in a mouse lung cancer model (27). Since TIMP-1 
expression controls lung cancer cell proliferation (Fig. 6E), we hypothesized that inhibition of 
NFkB signaling would phenocopy p38α inhibition. Treatment of soft agar colonies formed by 
	 11	
mKLC cells with an inhibitor of IKK2, a kinase upstream of p65 NFkB, resulted in decreased 
colony size, which was further decreased by the combined treatment with both p38α and IKK2 
inhibitors (See SI Appendix, fig. S5G). Altogether, these results support a key role for TIMP-1 in 
Kras-driven lung cancer, indicating that TIMP-1 promotes epithelial lung cancer cell 
proliferation in an autocrine manner, and that both p38α and NFkB signaling contribute to 
TIMP-1 production by epithelial cancer cells. 
 
DISCUSSION 
Given the plethora of cellular processes that p38a can regulate, its role in tumorigenesis has been 
hard to define. Depending on the nature of the stimulus, the cell type and the malignant stage, 
p38a is involved in cell death or survival, cell cycle entry or induction of cell differentiation, 
(11, 31). Therefore, it is difficult to predict which tumors could benefit from p38a inhibition 
without performing in vivo experiments.  
Here, we use mouse models of KRAS-driven NSCLC to show that p38a plays a dual role 
during lung tumorigenesis. We provide evidence that p38a plays a tumor suppressor function in 
normal lung epithelial cells, interfering with KrasG12V-driven malignant transformation. In this 
case, p38a maintains the homeostasis by balancing proliferation and differentiation capacities of 
alveolar progenitors (9), and maybe also by mediating senescence entry induced by oncogenic 
Kras expression, as shown in cultured fibroblasts (32) (33). Therefore, in the absence of p38a 
there is an increased number of poorly differentiated epithelial cells with the potential to become 
tumor initiating cells (9). In addition to the deregulated proliferation of the progenitor cells, 
p38a-deficient lungs have an enhanced immune response, as indicated by the increased number 
of CD45+ cells recruited. These immune cells probably belong to the myeloid lineage (8), and 
collaterally contribute to tumor-promoting inflammation. Despite the benefits that the 
downregulation of p38a would entail a priori for tumor development, lung cancer cells do not 
seem to shut off this anticancer signaling pathway. Instead, we detect increased phosphorylated 
p38α in lung tumors compared to paired healthy parenchyma, which agrees with previous reports 
on NSCLC patients (14-16). Moreover, we show that higher p38a levels correlate with poor 
overall survival and with recurrence in lung adenocarcinoma, as it was proposed for colorectal 
cancer (34). Our results indicate that during tumor progression, lung cancer cells get advantage 
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of the ability of p38a to regulate targets like TIMP-1, a metalloproteinase inhibitor that not only 
regulates extracellular matrix catabolism but also promotes cell proliferation and survival in an 
autocrine manner. This latter function of TIMP-1 is based on both the regulation of the 
pericellular availability of protease-dependent growth factor or cytokine signals, and the binding 
to CD44/pro-MMP9 or to CD63, which in turn can stimulate ERK, FAK, YAP/TAZ and PI3K 
signaling pathways (35, 36). Accordingly, clinical studies have positively correlated high Timp-1 
expression levels with poor prognosis in lung and colon cancer patients, as well as with short 
relapse-time and advanced-stage tumors from breast and brain origin (37).  
It has been reported that the IKK2/NFkB and p38 MAPK/ATF-2 pathways can both 
induce Timp1 transcription in IL-1-stimulated human astrocytes, consistent with the presence of 
AP-1, NFkB and ATF-2 binding sites on the Timp1 promoter (30). A previous study also showed 
that IKK2 downregulation decreases tumor cell proliferation in a mouse model of lung cancer, 
which correlates with decreased expression of TIMP-1 (27), mirroring the phenotype of p38α 
downregulation. Here we show that chemical inhibition of either p38a or IKK2 impairs the 
proliferation of epithelial lung cancer cells in soft agar. Of note, p38α and NFkB can 
coordinately control the expression of several genes, such as the CXCL10 cytokine (38, 39), 
which we also found downregulated in p38a-deficient lung tumors. In fact, p38α has been 
reported to target IkBα for degradation (40), and to modulate the acetylation of p65, hence 
controlling the transcriptional activity of NFkB (41). Therefore, it seems likely that both 
pathways might perform overlapping functions in lung tumor progression. It would be interesting 
to test whether the combined inhibition of p38a and IKK2 could prevent any compensatory 
cross-talk and suffice to trigger lung tumor regression instead of the cytostatic effect observed 
upon inhibition of either single pathway alone.  
Our studies identify p38a as a synthetic lethal interactor of KrasG12V in lung epithelial 
cancer cells, suggesting its potential interest as a therapeutic target. As prove of concept, we used 
the p38a pharmacological inhibitor PH-797804 that reached phase II clinical trials for chronic 
obstructive pulmonary disease (42). Treatment with PH797804 showed that p38a activity is 
required for the progression of genetically-induced lung tumors to advanced stages. In addition, 
orthotopic xenograft experiments indicated that epithelial cancer cells rely on p38a signaling to 
proliferate within the pulmonary niche in vivo. Although metastatic properties of lung cancer 
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cells do not seem to depend on p38α, our results indicate that the malignancy and size of the 
lung tumor mass is ultimately determined by the epithelial p38α levels. This dependency on 
p38a is highlighted by the anchorage-independent proliferation assays using lung epithelial 
cancer cells ex vivo, and agrees with a report for signet-ring carcinoma cell lines that also form 
smaller colonies when treated with the p38 MAPK inhibitor SB203580 (43). Taken together, our 
data indicate a pro-tumorigenic function of p38a in epithelial cancer cells of KRAS-driven lung 
tumors. 
There is evidence that p38a can also mediate non-cancer cell autonomous functions in 
lung tumors. Ubiquitous expression of a non-phosphorylatable p38a mutant has been reported to 
impair the synthesis of hyaluronic acid by cancer-associated fibroblasts, reducing lung cancer 
cell proliferation (21). p38a can also regulate PD-L1 expression in KrasG12V-driven cancer cells, 
thus impairing the tumor immunosurveillance capacity (44). Moreover, p38a might control the 
ability of infiltrating myeloid cells to contribute to lung adenocarcinoma progression, as 
described in colon cancer via IGF-1 production (45). Therefore, p38α seems to control the 
production of different extracellular factors that will build autocrine and reciprocal signaling 
circuitries between stromal and cancer cells, in a way comparable to the circuitry established by 
human lung stem cells and their niche (46). These results support the use of pharmacological 
inhibitors of p38a to target pro-tumorigenic functions of both cancer cells and stromal cells in 
lung tumors.  
Whether the dependency on p38a for lung tumor progression is restricted to KRAS 
mutant tumors or it applies to other lung tumors independently of the driver mutation remains to 
be investigated. In the case of lung tumors with non-functional p53, which account for about half 
of NSCLC cases (47), it has been reported that mice systemically expressing non-
phosphorylatable p38α show decreased KrasG12D-induced tumor burden (21). Moreover, our 
results using the human cancer cell lines H460 (p53wt) and H358 (p53-deleted) suggest that 
epithelial p38α facilitates soft-agar growth independently of the p53 status. It should be also 
noted that p38a has been reported to facilitate resistance of lung tumors to cisplatin in vivo in 
both p53-proficient and -deficient mouse models (48, 49). Therefore, the requirement for p38a 
signaling in cancer cell fitness and in its interaction with the stroma is likely to represent a 
selective difference between normal cells and cancer cells in different tumor types, which can be 
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Mice. Kras+/FSFG12V mice (23) were crossed with Mapk14lox/lox (9, 50), Mapk14+/- (51) and UBC-
Cre-ERT2 mice (52) to obtain the genotypes Mapk14lox/lox;Ub-CreERT2;Kras+/FSFG12V and 
Mapk14lox/-;Ub-CreERT2;Kras+/FSFG12V, which both gave indistinguishable phenotypes. 
Kras+/FSFG12VMapk14lox/lox were alternatively crossed to Sftpc-Cre-ER mice (53) to obtain mice 
with lung-specific p38a downregulation (p38a-ΔSPC). The two p38a deficient mouse lines were 
on a mixed C57BL/6-FVB background and showed indistinguishable lung phenotypes, as 
determined by histology studies. Littermate controls of both sexes were used in all experiments. 
Mice were housed according to the national and European Union regulations, and protocols were 
approved by the animal care and use committee of both the Barcelona Science Park (PCB) and 
Biomedical Research Park of Barcelona (PRBB). 
 
Generation of mKLC cells and p38a downregulation ex vivo. Primary adenocarcinomas 
generated in Mapk14lox/lox;Kras+/FSFG12V mice were orthotopically implanted in Crl:NU-Foxn1nu 
mice as previously described (26). A freshly collected fragment of lung tumor was minced with 
sterile scalpels and then was plated in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 20% fetal bovine serum (FBS) plus 1% penicillin/streptomycin. Medium was 
renewed once a week until colonies with epithelial cell morphology were observed. Then cells 
were trypsinized and expanded as established cell lines. 
To downregulate p38a, mKLC cells with Mapk14lox/lox alleles were treated with Tat-Cre 
recombinant protein (54) at a concentration of 150 µg/ml in serum-free DMEM with 1% 
penicillin/streptomycin. After 10 h, medium was replaced with DMEM 10% FBS, and cells were 
passaged twice before performing experiments. For mKLC cells carrying both Mapk14lox/lox 
alleles and inducible Cre-ERT2, p38a downregulation was induced by treating with 4OHT-TMX 
(10 µM, Sigma #H6278) for 3 days. 
 
Orthotopic implantation. Immunocompetent mice were anesthetized, intratracheally inoculated 
with 100 µl of a 2x106 mKLC cells/ml solution, and tumors were left to grow for 25 days. For 
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intratracheal administration, cells were cultured to 70% confluence in DMEM 10% FBS, diluted 
with PBS, kept on ice, and thoroughly mixed prior to each inoculation. The vocal cords were 
viewed directly with the help of a cold light source, and a blunted catheter coupled to a syringe 
was passed beyond them to inoculate the cells. 
 
Histopathological analysis and immunohistochemistry. Mouse lungs were fixed by 
insufflating 10% neutral buffered formalin (Sigma) through the trachea with a syringe, incubated 
overnight at 4°C in 10 ml 10% neutral buffered formalin, and then embedded in paraffin. Tumors 
in freshly harvested lungs were counted and sized, and lung sections stained with hematoxylin 
and eosin (H&E) were analyzed for tumor grade by two independent observers in a blinded 
fashion. Tumor grade was evaluated following established classifications (55). The human lung 
cancer tissue array (US Biomax Inc., HLug-Ade050CD-01) included lung adenocarcinoma 
samples with adjacent normal tissues, and samples of normal lung from patients without tumor. 
After staining, it was evaluated blindly by three independent observers. Slides were incubated 
using the following antibodies: CD31 (Abcam # 28364; 1:500), CD45 (BD biosciences #550539; 
1:100), CD68 (Biorbyt #47985; 1:750), Cleaved Caspase-3 (Cell Signaling #9661; 1:500), Ki67 
(Novacastra, #NCL-Ki67p; 1:500), p38a (Cell Signaling #9218; 1:50), phospho-Thr180/Tyr182 
p38 MAPK (Cell Signaling #4631; 1:50), phospho-Thr334 MK2 (Cell Signaling #3007; 1:100), 
phospho-Tyr705 STAT3 (Cell Signaling #9145S; 1:200), pro-SPC (Millipore #AB3786; 
1:3000), and HRP conjugated secondaries (ImmunoLogic and Dako). Immunostaining was 
visualized with 3, 3-diaminobenzidine, and counterstained with hematoxylin, or subsequently 
incubated with Alexa-conjugated secondary antibodies (Life Technologies #A21441; 1:400). To 
detect apoptosis in paraffin-embedded samples, the Fluorescein in situ cell death detection kit 
(Roche #11684795910) was used according to manufacturer’s instructions.  
Whole digital slides were acquired with a slide scanner (Nanozoomer, Hamamatsu), and 
individual images were captured with NDP view software. All tumors in each tissue section were 
analyzed. Positive signals were quantified in an automated manner based on either the relative 
percentage of stained surface in a tumor or the relative percentage of positive cells per tumor, 
using computerized imaging software (Image J). 
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Statistical methods. Data are presented as means ± standard error of the mean (SEM), unless 
otherwise indicated. Dataset statistics were analyzed with Prism 7 (GraphPad software). Groups 
were compared using the two tailed Mann-Whitney test or the analysis of variance (ANOVA, 
Kruskal-Wallis). p values smaller than 0.05 were considered statistically significant: *, p<0.05, 
**, p<0.01, ***p, <0.001, ****, p<0.0001. 
 
Data availability statement. All data discussed in the paper will be made available to readers.  
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Fig. 1. High levels of p38a expression correlate with malignancy and poor prognosis. (A) 
Boxplots for expression levels of MAPK14 mRNA comparing paired adenocarcinomas and 
healthy tissues (n≥49 per group). a.u., arbitrary units. (B) Kaplan–Meier plots showing a 
univariate analysis of overall survival of lung adenocarcinoma patients stratified by high or low 
MAPK14 mRNA expression (n≥39 per group). (C) Kaplan-Meier plots displaying a recurrence-
free survival over time of lung adenocarcinoma patients stratified by high or low MAPK14 
mRNA expression (n≥26 per group). (D) Representative images and boxplot of the percentage of 
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phospho-p38+ cells in lung adenocarcinoma tumors (n=17), paired normal tissue (n=14) and 
healthy lung parenchyma (n=5) from a human tissue array. Scale bar, 200 µm. (E) Same samples 
as in (D) were stained with a p38a antibody by immunofluorescence. Dapi marks nuclei. (F) 
Representative image of a murine KrasG12V-driven lung tumor stained with phospho-p38 
antibody. Scale bar, 200 µm. The histogram shows the percentage of phospho-p38+ cells in 
tumors and in healthy lung parenchymas (n=5 healthy tissues and 21 tumors from 6 different 








Fig. 2. p38a-ΔSPC mice show increased tumor burden but delayed progression to advanced 
stages. (A) Schematic representation of the experimental treatment regime. Ad-FlpO, adenovirus 
expressing FlpO recombinase; TMX, tamoxifen; i.p., intraperitoneal injection; i.t. intratracheal 
administration. (B) Representative images of WT and p38a-ΔSPC lungs stained for the AE2 
marker SPC, or with Ki67 antibody to detect proliferative cells. Bar, 100 µm. The histogram 
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shows the quantification of the percentage of Ki67+ cells per tumor (n=50 WT and 47 p38a-ΔSPC 
tumors, from 5 different mice each). (C) Representative images of WT and p38a-ΔSPC lungs 
stained with CD45 antibody to estimate the degree of immune cell infiltration. Bar, 100 µm. The 
histogram shows the quantification of the CD45+ area as a percentage of the total area analyzed 
(n=30 WT and 56 p38a-ΔSPC tumors, from 3 different mice each). (D) Representative images of 
WT and p38a-ΔSPC lungs stained with H&E. Dot plots show the quantification of the tumor area 
(n≥4 mice). Bar, 2 mm. (E) Tumors were microscopically analyzed and classified according to 
their pathological stage as adenocarcinoma (ADC), adenoma (AD), and atypical adenomatous 










Fig. 3. p38a enables KrasG12V-driven lung tumor progression. (A) Representative immunoblots 
with antibodies to p38a and phospho-p38 (P-p38) of whole lung lysates from WT and p38a-
deficient mice, as indicated by - and + tamoxifen (TMX), respectively, either expressing or not 
KrasG12V. Tubulin was used as loading control. Each line corresponds to one mouse. (B) 
Schematic representation of the experimental treatment regime. Ad-FlpO, adenovirus expressing 
FlpO recombinase; i.p., intraperitoneal injection; i.t. intratracheal administration. (C) 
Representative images of WT and p38a-ΔUb lungs stained with H&E. Bars, 2 mm. Dot plots 
show the quantification of both the tumor number and the number of tumors bigger than 1 mm in 
diameter per animal, before (Initial) and 2 weeks after the TMX treatment in WT and p38a-ΔUb 
mice (n≥9 mice per group). (D) Tumors as in (C) were microscopically analyzed and classified 
according to their pathological stage as adenocarcinoma (ADC), adenoma (AD), and atypical 
adenomatous hyperplasia (AAH). n≥6 mice per group. (E) Representative images of WT and 
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p38a-ΔUb lungs collected one week after TMX injections and stained with Ki67 antibody to 
detect proliferative cells. Bar, 100 µm. The histogram shows the quantification of Ki67+ cells as 
a percentage of the total number of cells counted per tumor (n=37 WT and 27 p38a-ΔUb tumors, 















Fig. 4. Chemical inhibition of p38a impairs the growth of KrasG12V-driven lung 
adenocarcinomas. (A) Representative images of H&E stained lungs from animals treated with 
vehicle or the p38a inhibitor PH797804 (p38i). Bar, 2 mm. Dot plots show the quantification of 
both the tumor number and the number of tumors bigger than 1 mm in diameter per animal, 
before (Initial) and after 2 weeks of treatment with vehicle or p38i. n≥10 mice per group. (B) 
Lungs with tumors from KrasG12V-expressing animals that were administered vehicle or p38i for 
15 days, were treated with NaCl ex vivo to hyperactivate the p38a pathway or left untreated, and 
then were immunoblotted with the indicated antibodies. Each pair of lines (- +) corresponds to 
one mouse. Representative examples are shown. (C) Tumors were microscopically analyzed and 
classified according to their pathological stage as adenocarcinoma (ADC), adenoma (AD), and 
atypical adenomatous hyperplasia (AAH). n=3 mice. (D) Representative images of lung tumors 
from animals treated with vehicle or p38i for 15 days that were stained with Ki67 antibody to 
detect proliferative cells. Bar, 100 µm. The histogram shows the quantification of Ki67+ cells per 
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tumor as a percentage of the total number of cells counted (n= 70 Vehicle- and 33 p38i-treated 














Fig. 5. Epithelial p38a is necessary for the proliferation of lung tumor cells. (A) WT and p38a-
ΔmKLC cells derived from mouse lung tumors were seeded in soft agar. Histograms show the 
number of colonies formed, their average diameter, and the percentage of colonies bigger than 
150 µm per well (n≥42 colonies analyzed). Data represent mean ± SD. (B) Representative 
images of phospho-MK2 immunostainings of lung tumors formed by intratracheal inoculation of 
WT and p38a-ΔmKLC cells. Bar, 100 µm. (C) Representative images of H&E stained lungs from 
WT animals that were intratracheally inoculated with either WT or p38a-ΔmKLC cells. Bar, 2 mm. 
Dot plots show the average number of total tumors, and the number of tumors with a diameter 
bigger than 1 mm 22 days after the intratracheal inoculation (n≥12 mice per group). Data 
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represent average ± SEM. (D) Representative images of lung tumors from mice that were 
intratracheally inoculated with either WT or p38a-ΔmKLC cells and were stained with Ki67 
antibody. Bar, 100 µm. The histogram shows the quantification of Ki67+ cells per tumor as a 
percentage of the total number of cells counted (n=55 WT and 70 p38a-ΔmKLC tumors, each from 
≥5 mice). Data represent average ± SEM. (E) Representative examples of lungs from mice that 
were intratracheally inoculated with either WT or p38a-ΔmKLC_CRE-ERT2 cells, and 22 days later 
were treated with tamoxifen. Lungs were stained with H&E 15 days after p38a downregulation. 
Bar, 2 mm. Dot plots show the quantification of both the tumor number and the number of 








Fig. 6. p38a-regulated expression of TIMP-1 induces lung cancer cell proliferation. (A) Relative 
TIMP-1 protein levels in lung tumors from mice that were intratracheally inoculated with either 
WT or p38a-ΔmKLC cells, as determined using a cytokine array (n=20 tumors from 4 mice per 
condition analyzed in a single array). (B) Relative Timp1 mRNA expression in tumors from WT 
and p38α-ΔUb mice (n=4 tumors from ≥3 mice per group). (C) Representative immunoblots with 
antibodies to TIMP-1 and tubulin as a loading control of whole lung lysates from WT and p38α-
ΔUb mice, as indicated by - and + tamoxifen (TMX), respectively, either expressing or not the 
KrasG12V oncogene. Each line corresponds to one mouse. (D) Histogram showing Timp1 
downregulation in WT mKLC cells treated with shRNAs targeting Timp1 (sh#1 and sh#2) or a 
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non-targeting control (shNT). (E) Representative images of the soft agar colonies formed by WT 
mKLC cells treated as in (D) in the presence or absence of recombinant TIMP-1 protein (rTIMP-
1, 0.1 µg/ml) added twice a week. Bars, 150 µm. The histogram shows the average colony 
diameters (n≥52 colonies analyzed per group from 3 replicates). (F) Representative images of the 
soft agar colonies formed by WT cells, p38a-ΔmKLC cells, and p38a-ΔmKLC cells treated with 
rTIMP-1 protein (0.1 µg/ml) twice a week. Bars, 150 µm. The histogram shows the average 
colony diameters (n≥144 colonies analyzed per group from 6 replicates). (G) Average diameters 
of the colonies formed by the human NSCLC cell line H460 grown in soft agar for 20 days and 
treated with vehicle, the p38a inhibitors SB203580 (SB) and PH797804 (PH), or with PH plus 
0.1 µg/ml rTIMP-1 protein (≥119 colonies analyzed per group from 3 replicates). Data represent 
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Biostatistical analysis of lung cancer patient cohorts. The gene expression omnibus (GEO) 
repository (1) was searched for microarray and survival data of NSCLC samples. The data set 
GSE10072 was processed in Bioconductor using RMA (2, 3) and the expression levels of the 
p38a encoding gene (MAPK14) in lung tumor samples and paired healthy parenchyma were 
analyzed. GSE31210 was used for determining TIMP1 expression in relation to MAPK14 levels. 
GSE8894 (series matrix data) and GSE30219 (RMA normalized adjusted data (4)) were used for 
assessing the prognostic value of MAPK14. The probe set used for MAPK14 was 210449_x_at. 
Lung adenocarcinoma patient samples were split by median expression level and the two patient 
cohorts were compared by Kaplan–Meier survival plot, using Cox regression with 95% 
confidence intervals and log-rank P value with the R survival package 2.37.2. 
 
Induction of Kras-driven tumors and p38a downregulation in vivo. Eight to twelve week old 
mice were intratracheally inoculated (5, 6) with a single dose (100 µl) of FLP recombinase-
expressing adenovirus (109 pfu Ad-5CMV-FlpO/mouse, from Iowa University, Iowa, USA) 
under anesthesia (i.p. injection of 75 mg/kg ketamine, 1 mg/kg medetomidine, with a posterior 
recovery using 2 mg/kg atipamezol s.c.).  
To activate the tamoxifen-inducible Cre recombinase, mice were intraperitoneally 
injected tamoxifen (12.5 mg/ml, Sigma #T5648), dissolved in a mix 1:9 of ethanol (Panreac): 
corn oil (Sigma). Doses of 0.125 mg/g body weight were injected for five consecutive days. 
p38α downregulation was confirmed one week after the last injection.  
The inhibitor of p38a, PH797804 (Selleckchem #S2726) was dissolved at a 
concentration of 1.75 mg/ml in PBS containing 0.5% methylcellulose (Sigma) and 0.025% 
Tween20 (Sigma). Mice were weighed and a daily dose of 17.5 mg/kg body weight was 
administered by oral gavage for 15 consecutive days. Control mice were administered the vehicle 
solution. The inhibition of p38a was confirmed by immunoblotting 6 h after the last dose, using 
lysates of lungs incubated with or without NaCl (300 mM) for 15 min. 
 
Cytokine array analysis of tumor lysates. Five dissected tumors from four different mice of 
each genotype were pooled together and lysed in 80 µl of buffer (PBS with 10 µg/ml aprotinin, 
 3 
10 µg/ml leupeptin, and 10 µg/ml pepstatin) using the Precellys cell disruptor (Bertin 
Technologies). Triton X-100 was added to a final concentration of 1%, and lysates were frozen 
at -80°C overnight. Protein content was quantified for each pool with the DC Protein assay kit 
(BioRad) and 1.6 mg of protein were loaded onto the Cytokine profiler array membranes (R&D 
Systems #ARY006), following the manufacturer’s instructions. Pixel densities on developed X-
ray film were collected and analyzed using a transmission mode scanner and image analysis 
software (Image J). 
 
Cell culture 
Murine mKLC cells and LLC1 cells were maintained in DMEM (Sigma, #D5796). Human 
NSCLC cell lines H358 and H460 were grown in RPMI 1640 (Sigma, #8758). In all cases media 
was supplemented with 10% heat inactivated FBS (Thermo Fisher Scientific), 1% L-glutamine 
(Thermo Fisher Scientific) and 1% penicillin/streptomycin (Gibco), and cells were grown at 
37°C and 5% CO2. All cell lines were tested for mycoplasma before performing the experiments 
by using the colorimetric kit from Lonza (#LT07-710). 
For chemical inhibition of p38a, cells were treated every 24 h with PH797804 (1 µM; 
Selleckchem #S2726) or every 48 h with SB203580 (10 µM, Axon MedChem #1363). For IKK2 
inhibition, cells were treated every 48 h with TPCA-1 (1 µM Sigma #T1452). Control cells were 
treated with DMSO vehicle. 
 
Viral infections and shRNA-mediated knockdown 
Cre-ERT2-expressing mKLC cells were generated by retroviral infection. Briefly, Cre-ERT2 
was cloned into pWZL-blasticidin (Addgene #150477) and the resulting plasmid was co-
transfected with pcL-Eco packaging vector (Addgene #12371) in HEK293T cells using CaCl2 
transfection. Culture supernatants were collected 48 h post-transfection, filtered (0.45 µm PVDF 
filter, Millipore), and centrifuged at 3000xg for 1 h at 4ºC (Amicon Ultra-15 #910024). 
Subconfluent mKLC cells were infected with one third of the recovered viral solution 
supplemented with 8 µg/ml polybrene (Sigma), and selected 48 h post-infection with 2 µg/ml 
blasticidin (Thermo Fischer Scientific #A1113903) added daily for 1 week. 
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  The following shRNAs were obtained from Sigma: Mapk14 #1 (TRCN0000023119), 
Mapk14 #2 (TRCN0000310885), Timp-1 #1 (TRCN0000080039), Timp-1 #2, 
(TRCN0000080042), Non-targeting control (SHC002). Lentivirus were produced in HEK293T 
cells co-transfected by CaCl2 with third generation lentiviral plasmids from Addgene together 
with the shRNA-encoding plasmids. 48 h post-infection, cells were selected by daily addition of 
1 µg/ml puromycin for 1 week. 
 
Soft agar assays. Semisolid proliferation media contained either 0.35% or 0.5% agarose in 
DMEM or RPMI 1640 with 10% FBS. The bottom of 6-well plates was homogeneously covered 
with 0.5% agarose, and when solidified, 2000 lung cancer cells were mixed with an equal 
volume of 0.35% agarose in DMEM or RPMI 1640 and plated on top of the previous layer. After 
solidification of the second layer, 1 ml of DMEM or RPMI 1640 10% FBS was added, and 
renewed once a week. After 20-30 days, the number of colonies per well was manually counted 
under a microscope and photographed for size analysis with Image J software. 
 
Adhesion, migration, anoikis and metastasis assays. Adhesion assays were performed in 24-
well plates uncoated or coated with either 10 µg/ml fibronectin or 10 µg/ml collagen I. Cells 
were labeled with Cell Tracker Green (Invitrogen #C7025) for 30 min at 37°C, and then were 
incubated in DMEM 0.5% FBS overnight. 5x104 cells in serum free media were added to each 
well of the 24-well plate, and after 2 h the wells were washed and adhered cells were fixed in 
formalin, photographed and counted. 
To assay cell migration, 4x104 cells, which had been grown overnight in DMEM 0.5% 
FBS, were seeded in DMEM 0.5% FBS on the upper part of Boyden chambers (Falcon 
#353097). The lower part of the chambers contained DMEM 10% FBS, or 0.5% FBS to be used 
as a control. After 20 h, the cells remaining on the upper part were removed, and the cells in the 
bottom part were fixed with 4% PFA, stained with crystal violet and counted. 
To measure anoikis resistance, the bottom of a 24-well plate was coated with 120 µl of 
0.03 g/ml poly-HEMA, and then 5x104 cells were seeded per well. After 48 h, cells were stained 
with trypan blue and counted under the microscope. 
For extravasation assays, HUVEC cells were grown for 4 days on the upper side of 
fibronectin pre-coated chambers (3 µm pore). LLC1 cells (1x105) were stained with Cell Tracker 
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Green (Invitrogen #C7025) and then were seeded on top of the HUVEC cells. After 12 h, the 
cells that were on the bottom part of the chamber were quantified. 
To analyze metastatic dissemination, 4.5x105 mKLC cells were subcutaneously injected 
into the rear flanks of 8-week old female athymic nude mice, and followed-up until they reached 
a maximum volume of 1 cm3 using a caliper. Thereafter, tumors were removed, incisions were 
closed, and the mice were kept for 15 more days to monitor metastatic foci formation in distal 
organs.  
In tail vein injection experiments, 9.5x105 LLC1 cells were injected in six weeks-old 
nude mice and the tumor burden was determined by measuring the percentage of tumor area in 
H&E stained lung sections using computerized image software (Image J). 
 
Flow cytometry assays. For the analysis of cell cycle profiles, trypsinized cells and their 
supernatant were centrifuged at 250xg for 5 min, washed with PBS and diluted to 106 cells/ml. 
330 µl of the cell suspension were thoroughly mixed with 660 µl of ice-cold absolute ethanol 
added drop-wise. After overnight incubation at 4°C, pellet was resuspended in 500 µl of DNA 
staining solution containing 0.2 mg/ml RNase A (Roche #109-169) and 20 μg/ml propidium 
iodide (Sigma #P4864). Cells were incubated for 30 min at 30°C in a water bath in the dark, and 
then run in a Gallios flow cytometer (Beckman Coulter). 
To measure BrdU incorporation, cells were pulsed for 90 min with 10 µM BrdU (Sigma 
#B9285), harvested, and resuspended in 500 µl PBS. 5 ml of cold 70% ethanol were added drop-
wise while agitating the tube, and cells were stored overnight in the freezer. Cells were then 
pelleted, washed and their DNA was denatured with 0.5 ml of 0.1 M HCl, 0.5% Tween 20 for 10 
min on ice and then washed and boiled. Cells were washed twice with 0.5% Tween, 1% BSA in 
PBS and then incubated with anti-BrdU-FITC antibody (BD Pharmingen #556028). After 
incubation for 30 min at RT in the dark, excess of antibody was washed out and cells were 
resuspended (106 cells in 400 µl) in PBS containing 2 mg/ml PI plus 5 mg/ml RNase A. Cell 
suspensions were run in a Gallios flow cytometer and analyzed using FlowJo software. 
EpCAM expression was analyzed by incubating mKLC cells with EpCAM-FITC (Santa 
Cruz #53532, 1:50) for 30 min on ice in the dark. Samples were run in a Gallios flow cytometer 
(Beckman Coulter). DAPI (1:100) was used for exclusion of dead cells and debris and doublets 
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were excluded by plotting forward-scattered (FSC) versus side-scattered (SSC) channels. Data 
was analyzed using FlowJo software. 
 
Immunoblotting. Lungs were harvested and immediately frozen in liquid nitrogen. A lobule was 
thawed on ice, mixed with lysis buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1% NP-40, 5 
mM EDTA, 5 mM EGTA, 20 mM NaF, 0.1 mM sodium orthovanadate, 1 mM DTT, 1 mM 
microcystin and the Protease Inhibitor Cocktail from Roche) and mechanically disrupted with a 
Precellys homogenizer (Bertin Technologies). The lysates were vortexed, incubated on ice for 10 
min and centrifuged for 15 min at 16,000xg 4°C. Supernatants were quantified using the Protein 
Assay kit (Bio-Rad) and 40 µg of total protein were mixed with Laemmli buffer, separated by 
SDS-PAGE and transferred to nitrocellulose membrane (Whatman). The following antibodies 
were used: E-cadherin (BD Biosciences #610181; 1:1000), p38a (Cell Signaling #9218; 1:1000), 
phospho-Thr180/Tyr182 p38 (Cell Signaling #9211; 1:2000), Hsp27 (Santa Cruz #SC-1049; 
1:1000), phospho-Ser82 Hsp27 (Cell Signaling #2401; 1:500), TIMP-1 (Cell Signaling #8946; 
1:200) and tubulin (Sigma #T9026), which was used as loading control. Alexa Fluor 680 or 800-
conjugated antibodies were used for detection (Invitrogen; 1:5000) and were visualized using 
Odyssey Infrared Imaging System (Li-Cor, Biosciences).  
 
Analysis of Mapk14 deletion. Genomic DNA was isolated from sorted cell populations or from 
lung tumors, and analyzed by qPCR with primers specific for exon 2 (floxed) and exon 12 (as a 
control) of the Mapk14 gene encoding p38a. Relative amount of exon 2 versus exon 12 was 
determined. Primers are indicated in the two bottom rows of Table S1. 
 
Quantitative RT-PCR. Total RNA was isolated from homogenized tumors, lung tissue, or 
isolated cells using the Purelink RNA minikit (Ambion #12183018A) following the 
manufacturer’s instructions. The total RNA was then treated with DNase I and reverse 
transcribed using the Superscript IV system (Invitrogen) with random primers. qRT-PCR was 
carried out in triplicate using a BioRad CFX96™ thermal cycler machine with the SYBR Green 
method (Applied Biosystems). Relative levels of mRNAs were measured by the ΔΔC(t) method 
and normalized against the housekeeping genes encoding glyceraldehyde-3-phosphate 
 7 
dehydrogenase (Gapdh) and hypoxanthine-guanine phosphoribosyltransferase (Hprt1). A 






Fig. S1. KRAS-driven lung tumor prognosis correlates with MAPK14 mRNA levels, but p38a-
downregulation in lung progenitor cells enhances KrasG12V-induced tumor size and inflammation. 
(A) Kaplan-Meier plots showing a univariate analysis of overall survival of KRAS-driven lung 
adenocarcinoma patients stratified by high or low MAPK14 mRNA expression (n=10 per group). 
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(B) Kaplan–Meier plots displaying a recurrence-free survival over time of KRAS-driven lung 
adenocarcinoma patients stratified by high or low MAPK14 mRNA expression (n>8 per group). 
(C) Representative images of WT and p38a-ΔSPC lungs stained with p38α antibodies. Bars, 100 
µm. (D) WT and p38a-ΔSPC mice were injected intraperitoneally with tamoxifen for 5 days and 
one week later AE2 cells were sorted as previously described (CD31- CD45- ITGB2+ SPC+ (7)). 
Genomic DNA was isolated and analyzed by qPCR for the relative copy number of exon 2 
(floxed) versus exon 12 (control) of the p38a-encoding Mapk14 gene (n=3 mice). (E) 
Representative images of lung sections from WT and p38a-ΔSPC mice that constitutively express 
a fluorescent Tomato-eGFP reporter (8). Cells without and with Cre activity are red (Tomato) 
and green (eGFP), respectively. Nuclei were labeled with DAPI (blue). Scale bar, 50 μm. (F) 
Weights of the lungs from healthy mice (No tumors) and KrasG12V-expressing WT and p38a-ΔSPC 
mice (n≥3 mice). (G) Representative images of WT and p38a-ΔSPC lungs stained with phospho-
STAT3 antibodies. Bars, 100 µm. The histogram shows the quantification of phospho-STAT3+ 
cells as a percentage of the total number of cells counted per tumor (n≥11 tumors from ≥3 mice 






























Fig. S2. p38a downregulation does not induce apoptosis, affect angiogenesis or impair immune 
infiltration in lung tumors. (A) Genomic DNA was isolated from individual tumors either from 
WT or p38a-ΔUb mice and the relative copy number of exon 2 (floxed) versus exon 12 (control) 
of the p38a-encoding Mapk14 gene was analyzed by qPCR (n≥4 tumors). (B) Representative 
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immunoblots with antibodies to p38a and tubulin as a loading control from individual lung 
tumors that were collected one week after the tamoxifen treatment. Each line corresponds to one 
mouse. (C) Total number of tumors and number of tumors bigger than 1 mm in diameter before 
(Initial) and one week after tamoxifen treatment in Mapk14+/+;Kras+/FSFG12V (WT) and 
Mapk14+/+;UBC-Cre-ERT2;Kras+/FSFG12V (UbCre) mice (n≥3 mice). (D) Representative images of 
lung tumors from WT and p38a-ΔUb mice that were collected one week after the last tamoxifen 
injection and were analyzed for lymphocyte (CD3), alveolar macrophage (CD68) and endothelial 
cell (CD31) markers. Bars, 100 µm. The histograms show the quantifications as the percentages 
of stained surface per tumor (n≥19 tumors from ≥3 mice per group). (E) Representative images 
of lung tumors from WT and p38a-ΔUb mice stained for TUNEL. Stained cells are indicated with 
white arrowheads. Bars, 100 µm. The histogram shows the quantification of apoptotic cells as a 
percentage of the total number of cells counted per tumor (n≥24 tumors from ≥3 mice per 
group). (F) Representative images of lung tumors from WT and p38a-ΔUb mice stained for 
cleaved caspase 3. Stained cells are highlighted with black arrowheads. The indicated areas are 
magnified in the lower panels. Bars, 200 µm (upper) and 50 µm (lower). Data represent average 






























Fig. S3. p38a deficient lung cancer cells have impaired ability to grow in soft agar. (A) FACs 
analysis of mKLC cells for the EpCAM epithelial marker. (B) Representative immunoblots with 
antibodies to p38a, E-cadherin and tubulin as a loading control of WT and p38a-ΔmKLC cells. (C) 
Representative cell cycle profiles of WT and p38a-ΔmKLC cells. (D) WT and p38a-ΔmKLC cells 
were labelled with BrdU and analyzed by flow cytometry (n=8). (E) Representative immunoblots 
of p38a expression in LLC1 cells expressing shRNAs targeting p38a (#1 and #2) or a non-
targeting control (NT). Tubulin was used as loading control. (F) Cells in (E) were labelled with 
BrdU and analyzed by flow cytometry (n=3). (G) Six weeks-old female mice were injected 
subcutaneously into the rear flanks with 2x105 LLC1 cells expressing shRNAs targeting p38a 
(#1 and #2) or a NT control, and tumor size was measured after 15 days (n≥5). (H) mKLC cells 
with Mapk14 floxed alleles and either with or without Cre-ERT2, as indicated, were grown for 
15 days in soft agar and colony diameters were measured. Then, 4-hydroxytamoxifen (4OH-
TMX) was added or not to the culture media every 3 days and the colony diameters were 
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measured again two weeks later (n=3). Control 4OH-TMX indicates cells without Cre-ERT2 
alleles that were treated with 4OH-TMX. Representative immunoblots of p38a expression in 
mKLC cells treated as indicated are shown in the left panel. Tubulin was used as loading control. 
(I) Diameter of the colonies formed by the human NSCLC cell line H358 grown in soft agar for 
30 days in the presence of the p38a inhibitors SB203580 (SB) and PH797804 (PH) or vehicle 




























Fig. S4. p38a downregulation does not affect the metastatic properties of mKLC lung cancer 
cells but controls the growth of the tumor mass. (A) Number of WT and p38a-ΔmKLC cells 
attached to uncoated, fibronectin-coated, and collagen-coated plates 90 min after seeding (n=8). 
(B) Number of WT and p38a-ΔmKLC cells per field that migrated to the bottom of Boyden 
chambers after 20 h (n=3). (C) WT and p38a-ΔmKLC cells were cultured for 48 h in non-adherent 
conditions to analyze anoikis resistance (n= 4). (D) LLC1 cells expressing shRNAs targeting 
p38a (#1 and #2) or a non-targeting control (NT) were seeded on Boyden chambers coated with 
fibronectin and HUVEC cells, and 12 h later the cells that extravasated to the lower part of the 
chamber were counted. Numbers are normalized to shNT cells (n=4). (E) Representative images 
of H&E stained lungs with metastatic foci formed in immunodeficient mice that were 
subcutaneously injected with WT or p38a-ΔmKLC cells. Bar, 2 mm. Dot plots show the 
quantifications of the number of lung metastatic foci per mice counted 15 days after primary 
tumor resection (n≥4 mice). (F) Representative H&E staining of lungs 15 days after intravenous 
injection of LLC1 cells expressing shRNAs targeting p38a (#1 and #2) or a NT control. Bar, 2 
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mm. Percentage of tumor area relative to the total lung area in each mouse is indicated (n≥4 































Fig. S5. TIMP-1 regulation by p38a controls lung cancer cell proliferation. (A) Twenty lung 
tumors from four different mice that were intratracheally inoculated with either WT or p38a-
ΔmKLC were lysed together and analyzed using a cytokine array. The histogram shows the fold 
change in pixel density of the ten most highly deregulated cytokines in p38a-ΔmKLC tumors. 
Expression levels in WT tumors were given the value of 1. Internal array controls are indicated. 
(B) Analysis of Timp1 mRNA expression by qRT-PCR in lung tumors from mice that were 
intratracheally inoculated with WT or p38a-ΔmKLC cells (n=4). (C) Analysis of cytokines’ mRNA 
expression by qRT-PCR in the lung tumors from WT or p38a-ΔmKLC mice (n=2). (D) Timp1 
mRNA expression in lung epithelial cancer cells isolated from tumors of mice inoculated with 
WT or p38a-ΔmKLC cells (n=2 mice). (E) Average colony diameters of mKLC cells grown in soft 
agar and treated with vehicle or the p38a inhibitors SB203580 (SB) and PH797804 (PH), either 
alone or together with 0.1 µg/ml of recombinant TIMP-1 protein (rTIMP1) added twice a week 
(n≥95 colonies analyzed per group from 3 replicates). (F) Boxplot for TIMP1 mRNA levels 
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according to MAPK14 mRNA levels in lung adenocarcinoma patient samples (n≥110 per group). 
(G) Average colony diameters of mKLC cells grown in soft agar and treated with either vehicle, 
the IKK2 inhibitor TPCA-1, the p38a inhibitor PH, or both together (n≥67 colonies analyzed per 
group from 3 replicates). Data represent average ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, 











Table S1. Primers used for qPCR  
 
Gene Forward  Reverse  










Il1a   CGAAGACTACAGTTCTGCCATT GACGTTTCAGAGGTTCTCAGAG 
Timp1        GGTGTGCACAGTGTTTCCCTGTTT TCCGTCCACAAACAGTGAGTGTCA 
Tnfa   CGTCAGCCGATTTGCTATCT CGGACTCCGCAAAGTCTAAG 
Mapk14 exon 2   GCATCGTGTGGCAGTTAAGA GTCCTTTTGGCGTGAATGAT 
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